Purevax range now available in 0.5 ml presentation
Boehringer Ingelheim announces reduced volume 0.5 ml Purevax vaccines for cats, more convenient vaccination experience combined with same efficacy
Search
BI 764532: DLL3/CD3 T-cell engager
BI 764532: DLL3/CD3 T-cell engager
Survodutide US FDA Breakthrough Therapy phase 3 trials MASH
Boehringer receives U.S. FDA Breakthrough Therapy designation and initiates two phase III trials in MASH for survodutide
Phase II clinical trial weight loss results
Data shows nearly 19% weight loss in people with overweight or obesity in Phase II trial with survodutide (BI 456906)
Say no to the uninvited guests
Find out how to keep fleas, ticks and worms away from your cat.
Stefanie Bock-Kreilinger
Stefanie Bock-Kreilinger on developing her own path
New African Swine Fever Manual published
Boehringer Ingelheim joined forces with the leading veterinarians to fight African swine fever. The new African Swine Fever Knowledge Handbook published.
B7-H6/CD3 T-Cell Engager
B7-H6/CD3 T-Cell Engager
KISIMA® Cancer Vaccine
KISIMA® Cancer Vaccine
BI 764532: DLL3/CD3 T-cell engager | ep-NEC
BI 764532: DLL3/CD3 T-cell engager | ep-NEC
DLL3/CD3 T-cell engager
DLL3/CD3 T-cell engager
Research Beyond Borders overview
Learn more about how our Research Beyond Borders team is uncovering new ideas and new science.
A life in a day: the reality of living with lung cancer
Within the initiative “A life in a day”, Anna-Maria spent 24 hours in the shoes of a lung cancer patient to better understand the patient experience.
InPedILD_trial_enrollment
First patient enrolled in InPedILD™, a global Phase III trial assessing the dosing and safety profile of nintedanib in children and adolescents
AI&Data Science Fellowship Tuebingen
AI&Data Science Fellowship Tuebingen
Pets
Pets
Vienna
Vienna is a cornerstone within the company’s global R&D network, with a special focus on cancer research. On top of that, it is also a hub for biopharmaceutical development and production.
EMPERIAL-heart-failure-toplineresults
Update on the EMPERIAL-Reduced and EMPERIAL-Preserved studies, which assess exercise ability in adults with chronic heart failure with reduced and preserved ejection fraction
emperor-preserved-kidney-subanalysis
New kidney sub-analysis of EMPEROR-Preserved trial demonstrates significant improvement in heart failure outcomes regardless of kidney disease status
VSV-GP
VSV-GP
Livestock
Livestock
Empowering smallholder farmers
The LastMile initiative improves health equity in remote areas of Africa, increasing access to animal health resources for underserved farming communities.
NEJM-IL-36-Phase-1-GPP-data
Data published in The New England Journal of Medicine show rapid improvement of symptoms in patients with a rare form of pustular psoriasis
New vaccine against Bovine Respiratory Disease
Boehringer Ingelheim’s Bovalto Respi Intranasal is a new respiratory vaccine for active immunization of cattle against Bovine Respiratory Disease.
Boehringer Ingelheim Innovation Prize Video 2023
Boehringer Ingelheim's Innovation Prize provides valuable resources to help early-stage companies progress their science.